Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1988 1
1990 1
1996 1
1997 1
1998 1
1999 1
2000 1
2001 1
2004 1
2005 1
2006 1
2007 3
2008 2
2009 4
2011 2
2012 1
2013 3
2014 4
2015 5
2016 4
2017 3
2018 4
2019 1
2020 8
2021 7
2022 3
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Digestive System Carcinoma"
Page 1
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, and current guidelines do not recommend any specific treatments for these patients. ...Pat …
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previou …
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ. Javle M, et al. Oncologist. 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. Oncologist. 2023. PMID: 37390492 Free PMC article. Review.
Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers. Most selective FGFR inhibitors under investigation show reversible binding, and their activity is limited by acquired drug resistance. …
Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory canc …
Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.
Kaur J, Vijayvergia N. Kaur J, et al. Curr Oncol. 2023 Sep 21;30(9):8653-8664. doi: 10.3390/curroncol30090627. Curr Oncol. 2023. PMID: 37754542 Free PMC article. Review.
Immunotherapy, particularly immune checkpoint inhibitors, has shown remarkable success in various malignancies by harnessing the body's immune system to target and eliminate cancer cells. Immune checkpoint inhibitor clinical studies in GEP-NENs have yielded promising outco …
Immunotherapy, particularly immune checkpoint inhibitors, has shown remarkable success in various malignancies by harnessing the body's immu …
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC. Limousin W, et al. J Hepatol. 2023 Dec;79(6):1450-1458. doi: 10.1016/j.jhep.2023.08.017. Epub 2023 Aug 28. J Hepatol. 2023. PMID: 37647991
Another patient with H-CCK, high HER2 overexpression and a high homologous recombination score was treated with trastuzumab/olaparib and had stable disease. ...IMPACT AND IMPLICATIONS: The use of whole-genome/-exome and RNA sequencing in clinical practice has not been repo …
Another patient with H-CCK, high HER2 overexpression and a high homologous recombination score was treated with trastuzumab/olaparib …
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ. Lee CK, et al. Lancet Gastroenterol Hepatol. 2023 Jan;8(1):56-65. doi: 10.1016/S2468-1253(22)00335-1. Epub 2022 Oct 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36328033 Clinical Trial.
There were no treatment-related cardiac toxic effects or deaths. The overall health assessment (EuroQoL-VAS) score did not change significantly throughout the treatment. Sensory and motor neuropathy symptoms as assessed by the European Organization for Research and Treatme …
There were no treatment-related cardiac toxic effects or deaths. The overall health assessment (EuroQoL-VAS) score did not change sig …
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. Janjigian YY, et al. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15. J Clin Oncol. 2018. PMID: 30110194 Free PMC article. Clinical Trial.
We assessed the safety and efficacy of nivolumab and nivolumab plus ipilimumab in Western patients with chemotherapy-refractory esophagogastric cancers. PATIENTS AND METHODS: Patients with locally advanced or metastatic chemotherapy-refractory gastric, esophageal, o …
We assessed the safety and efficacy of nivolumab and nivolumab plus ipilimumab in Western patients with chemotherapy-refractory esoph …
Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H, Wang K, Wang X, Zhao H. Lin J, et al. Theranostics. 2021 Mar 4;11(10):4585-4598. doi: 10.7150/thno.56539. eCollection 2021. Theranostics. 2021. PMID: 33754015 Free PMC article.
Background: The genomic spectrum of biliary tract carcinoma (BTC) has been characterized and is associated with distinct anatomic and etiologic subtypes, yet limited studies have linked genomic alterations with personalized therapies in BTC patients. ...Conclusions: Extens …
Background: The genomic spectrum of biliary tract carcinoma (BTC) has been characterized and is associated with distinct anatomic and …
Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review.
An Y, Zhou J, Lin G, Wu H, Cong L, Li Y, Qiu X, Shi W. An Y, et al. Pathol Oncol Res. 2021 Jul 26;27:1609859. doi: 10.3389/pore.2021.1609859. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34381313 Free PMC article. Review.
Colorectal signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC) with unique characteristics. ...Understanding the special molecular mechanisms related to the aggressive biology of SRCC is of great importance, which may provide a theoretical basis …
Colorectal signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC) with unique characteristics. ...Understandi …
Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
Wang Y, Yang X, Wang Y, Xue J, Zhang N, Yang X, Cong N, Zhang J, Zhu C, Zhang L, Hou X, Zhao H. Wang Y, et al. Cancer Immunol Immunother. 2023 Jul;72(7):2197-2204. doi: 10.1007/s00262-023-03399-2. Epub 2023 Mar 1. Cancer Immunol Immunother. 2023. PMID: 36856834 Free PMC article.
This study aimed to assess the effectiveness and safety of RT combined with programmed death-1 (PD-1) inhibitors and lenvatinib in patients with relapsed or refractory advanced biliary tract carcinoma (BTC). METHODS: This retrospective study included patients with r …
This study aimed to assess the effectiveness and safety of RT combined with programmed death-1 (PD-1) inhibitors and lenvatinib in patients …
Laparoscopic total esophagectomy.
Swanstrom LL, Hansen P. Swanstrom LL, et al. Arch Surg. 1997 Sep;132(9):943-7; discussion 947-9. doi: 10.1001/archsurg.1997.01430330009001. Arch Surg. 1997. PMID: 9301605
PATIENTS: Between December 12, 1993, and December 1, 1996, 9 patients with a mean age of 61 years underwent laparoscopic esophagectomy. Indications were adenocarcinoma in 5, squamous cell carcinoma in 1, dysplastic Barrett esophagus in 2, and refractory stricture wi …
PATIENTS: Between December 12, 1993, and December 1, 1996, 9 patients with a mean age of 61 years underwent laparoscopic esophagectomy. Indi …
66 results